XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.06

+0.3%

Dec 26 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: opalapril who wrote (8596)	2/3/1999 9:15:00 PM
From: aknahow	Read Replies (1) of 17367

"One is to meet with the FDA prior to the meeting with the DSMB to get permission to continue providing Neuprex to everyone at the study sites on an open label basis" What does this mean!!!!!!!!!!!!!!!!!!!!!!!!!!!!! Or this? A second reason was that a complete halt in the trial would have put patients in the study at risk. This is clear, apparently no trick, just that it's only over when it's really over. that the end of the trial will be announced as soon as possible thereafter - no trick definitions of "end." At that point XOMA will have a rough mortality number and that after analysis she is hoping that the 95% certainly goal will be met, but, in any event, all of the data will be analyzed and that if favorable XOMA will push for expedited approval.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next